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Abstract. Aging in humans is a multi-factorial cellular process 
that is associated with an increase in the risk of numerous 
diseases including diabetes, coronary heart disease and cancer. 
Aging is linked to DNA damage, and a persistent source of 
DNA damage is exposure to ultraviolet (UV) radiation. As such, 
identifying agents that confer protection against DNA damage 
is an approach that could reduce the public health burden of 
age-related disorders. Metformin and resveratrol have both 
shown effectiveness in preventing several age-related diseases; 
using human A549 cells, we investigated whether metformin 
or resveratrol, alone or combined, prevent UVC-induced DNA 
damage. We found that metformin inhibited UVC-induced 
upregulation of p53, as well as downregulated the expression 
of two DNA damage markers: γH2AX and p-chk2. Metformin 
also upregulated DNA repair as evidenced by the increase in 
expression of p53R2. Treatment with metformin also induced 
cell cycle arrest in UVC-induced cells, in correlation with a 
reduction in the levels of cyclin E/cdk2/Rb and cyclin B1/cdk1. 
Compared to metformin, resveratrol as a single agent showed 
less effectiveness in counteracting UVC-elicited cellular 
responses. However, resveratrol displayed synergism when 
combined with metformin as shown by the downregulation of 
p53/γH2AX/p-chk2. In conclusion, the results of the present 
study validate the effectiveness of metformin, alone or with 
the addition of resveratrol, in reducing the risk of aging by 
conferring protection against UV-induced DNA damage.
Introduction
The notion that aging and the quality of longevity of living 
organisms including humans may be improved can be found 
in century-old historical records (1). The topic is of interest to 
social and public health experts as well as basic and clinical 
scientists. On the one hand, life expectancy of humans has 
clearly benefitted from modern day medical advances that 
have eradicated several diseases that at one time plagued 
humankind (2,3); on the other hand, it is known that two thirds 
of people die daily from age-related causes pointing to aging 
as the single most significant risk factor for many human 
diseases (4).
Do interventions and dietary modalities exist that can delay 
the onset of aging, or counteract the deleterious effects of envi-
ronmental insults impinging on the integrity of our genome, 
widely considered as a major risk factor for disease-associated 
aging? It is our hypothesis that disease-associated, subclinical 
aging (in relative terms) is a multistage biological process 
whose duration and manifestation can be dynamically regu-
lated by environmental and dietary, as well as genetic factors. 
As a corollary, therefore, age-related diseases can be managed 
in humans using agents that attenuate cellular responses to 
external agents capable of damaging the integrity of the DNA 
in the genome.
Accumulation of DNA damage is regarded as a cause 
for aging, tumorigenesis and other inheritable diseases (5). 
Exposure of cells to ultraviolet (UV) radiation results in 
the generation of DNA damage and lesions, which, if left 
unrepaired, can directly or indirectly lead to dysfunctional 
cellular events and possibly disease-associated aging. Multiple 
changes occur to counteract UV-induced DNA damage, 
including the upregulation and activation of transcription 
factor p53. p53 is known to play an essential role in control-
ling various downstream target genes, frequently as different 
sets by a stimuli-specific [ionizing radiation, UV or reactive 
oxygen species (ROS)] mechanism (6,7). Thus, UV-induced 
p53 mediates cell cycle arrest and DNA repair and changes 
the expression of ataxia telangiectasia mutated (ATM) protein 
kinase and γH2AX (H2AX phosphorylated on Ser139) which 
then can be used as indicators to monitor the ongoing DNA 
damage induced externally by exposure to UV or by endog-
enously generated reactive oxygen species (ROS) (8-11).
In this study, we used human A549 cells to test and vali-
date the ability of metformin and resveratrol, alone and in 
combination, to confer protection against exposure to UVC, 
known to contribute to aging by damaging genomic DNA. 
Metformin, with demonstrated efficacy to restore insulin sensi-
tivity in type II diabetes (12,13), was selected for its activity 
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in managing age-related diseases including cardiovascular 
disorders and cancer (14-19) by targeting the AMP-dependent 
protein kinase (AMPK) (20,21), and extension of lifespan (22). 
The choice of resveratrol (trans-3,4',5-trihydroxystilbene), 
found abundantly in grapes (23,24), was based on its plethora 
of biological activities (14-19), and documented antioxidant, 
anti-inflammatory (25-28) and anti-diabetic activities (29), as 
well as its ability to modulate and activate SIRT1, a key protein 
for the aging process (30-33), and prolongation of life span 
in mammals and other species (33-35). Results of our studies 
support the effectiveness of metformin, alone or combined 
with resveratrol, in reducing the risk of aging by conferring 
protection against UV-induced DNA damage.
Materials and methods
Reagents. Fetal calf serum, Eagle's minimum essential 
medium, penicillin and streptomycin were purchased from 
Cellgro, Inc. (Herndon, VA, USA). Metformin (1,1-dimeth-
ylbiguanide chloride) and resveratrol were obtained from 
Calbiochem (La Jolla, CA, USA) and LKT Laboratories 
(St. Paul, MN, USA), respectively. All other chemicals and 
solvents used were of analytical grade. Primary antibodies: 
p53, cyclin B1, cyclin E, cdk1, cdk2, Rb, p53R2, cdc25C, 
actin and secondary antibodies were purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Other 
antibodies for the present study were obtained from the 
following sources: serine-139-phosphorylated histone H2AX 
(Upstate Biotechnology, Inc., Lake Placid, NY, USA); p21 
(Cell Signaling Technology, Inc., Beverly, MA, USA); plk1 
(Invitrogen Corp., Carlsbad, CA, USA), and p-chk2 (Cell 
Signaling Technology, Inc.). All other chemicals and solvents 
used were of analytical grade.
Cell culture. The lung carcinoma cell line A549 was purchased 
from the American Type Culture Collection (ATCC; Rockville, 
MD, USA). Cells were maintained in Eagle's minimum essen-
tial medium supplemented with 2 mM glutamine and Earle's 
BSS adjusted to contain 1.5 g/l sodium bicarbonate, 0.1 mM 
non-essential amino acids and 1 mM sodium pyruvate and 
supplemented with 0.01 mg/ml bovine insulin and 10% fetal 
bovine serum. Cells were seeded at a density of 5x104 cells/ml 
and passaged by washing the monolayers with phosphate-buff-
ered saline (PBS) followed by a brief incubation with 0.25% 
trypsin/EDTA.
Preparation of chemicals and treatment. Metformin and resve-
ratrol were dissolved in dimethyl sulfoxide (DMSO) and stored 
at -80˚C as 500 and 50 mM stock, respectively. Treatments 
included: 0, 2.5 or 25 µM of resveratrol or 5 mM metformin 
alone or in combination (5 mM metformin + 2.5 µM resveratrol 
or 5 mM metformin + 25 µM resveratrol). For UV irradia-
tion experiments, the cells were first primed with metformin 
or resveratrol for 48 h and washed with PBS to remove the 
chemicals. The primed cells were exposed to 20 J/m2 UVC for 
10 sec, after which the UVC-exposed cells were maintained in 
culture for 4 h, and harvested for further analysis.
Preparation of cell extracts and western blot analysis. To 
determine the level of protein expression of various genes 
examined in the present study, control and treated cells were 
harvested and lysed in ice-cold RIPA buffer [50 mM Tris, 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1% 
deoxycholate, 0.1% SDS, 1 mM dithiothreitol and 10 µl/ml 
protease inhibitor cocktail from Sigma Chemicals (St. Louis, 
MO, USA)]. The protein concentration of the cell lysates was 
determined using the Coomassie protein assay kit (Pierce, 
Rockford, IL, USA) with BSA as the standard. The proteins in 
cell lysates were separated by 10% SDS-PAGE and transferred 
to a nitrocellulose membrane as previously described (36). 
The blots were incubated overnight with various primary 
antibodies, followed by incubation for 1 h with secondary anti-
bodies. The blots were detected with an ECL detection system 
(LumiGLO Peroxidase Chemiluminescent Substrate kit; KPL 
Biotechnology, Inc., Gaithersburg, MD, USA), quantified by 
densitometry and normalized against actin as the loading 
control as previously described (37).
Cell cycle analysis. Cell cycle phase distribution was assayed 
by flow cytometry as previously described (38-40); the histo-
grams obtained were quantified for the percentage of cells in 
the respective phases (G1, S and G2/M) of the cell cycle.
Results
Effects of resveratrol and metformin on DNA damage 
response under normal and UVC-induced conditions. DNA 
damage is an important factor contributing to carcinogen-
esis and the aging process. Resveratrol (18,19,23,41,42) and 
metformin (14,43) have each been reported to have beneficial 
effects against cancer cells, e.g., by suppressing proliferation 
and induction of apoptosis (44-47), and aging, e.g., prolonging 
life span in model systems (11,33,48-51). However, the effects 
of these two chemicals alone or in combination on p53 
expression in the context of UV-induced DNA damage have 
not been investigated. Accordingly we monitored changes 
in the level of total p53. A pronounced increase (~2.3-fold) 
in p53 expression was observed in the UVC-induced control 
cells compared to the non-exposed control cells (Fig. 1A), 
suggesting that exposure to UVC resulted in the induction 
of total p53. Correspondingly, no significant change in p53 
expression was observed in control cells treated with either 
resveratrol (2.5 and 25 µM) or metformin alone (5 mM) or in 
combination (2.5 or 25 µM resveratrol combined with 5 mM 
metformin) (Fig. 1A). In contrast, under the UVC exposed 
condition, treatments resulted in a decrease in p53 expression 
of 17-21% by resveratrol, ~60% by metformin and 59-74% by 
the combined treatment (Fig. 1A). These results are consistent 
with the interpretation that metformin alone or in combina-
tion with resveratrol can prevent UVC-induced p53 activation. 
Next, we tested whether resveratrol and metformin may induce 
DNA damage by affecting the integrity of genomic DNA 
by analyzing changes in the DNA damage marker γH2AX. 
In non-stressed cells, the combination of 5 mM metformin 
and 25 µM resveratrol resulted in ~15% decrease in γH2AX 
expression (Fig. 1B). Under the UVC-induced condition, a 
slight increase in γH2AX expression was observed in cells 
treated with 2.5 or 25 µM resveratrol (Fig. 1B). Surprisingly, 
metformin alone or in combination with resveratrol inhibited 
UVC-induced γH2AX expression (Fig. 1B). Thus, data on 
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prevention of DNA damage by metformin and/or resveratrol 
resulting from the exposure to UVC as assayed by γH2AX 
expression generally agreed with measurements of p53 
changes.
Changes in cell cycle phase transition and expression of 
specific signaling proteins impinging on cell cycle control by 
resveratrol and metformin under UVC-induced conditions. 
Alteration in p53 expression could induce an arrest in cell 
cycle progression. Since minimum effects on p53 resulted from 
treatment by resveratrol or metformin under non-UVC-induced 
conditions, we next focused only on cells exposed to UVC. We 
first determined the effects of resveratrol and metformin on 
cell cycle progression by flow cytometry. Metformin alone and 
in combination with a low dose of resveratrol caused a signifi-
cant decrease in the S phase cell population (13.7% in control 
vs. 8.8 and 7.3% in cells treated with 5 mM metformin alone 
and combined with 2.5 µM resveratrol, respectively). This 
decrease was accompanied by a concomitant accumulation 
in the G1 phase cell population (59.1% in control vs. 69.2 and 
70.9% in 5 mM metformin without and with addition of 2.5 µM 
resveratrol) (Table I). To gain additional information on the 
underlying causes for the observed cell cycle phase transition 
change, we measured levels of cell cycle regulatory proteins 
cyclin E/cdk2 specifically required for G1 and S phase transi-
tion by western blot analysis. Results in Fig. 2A showed that 
Table I. Effect of resveratrol or metformin on cell cycle dis-
tribution.
  UV (20 J/m2)
Treatment G1 S G2/M
Control  59.1 13.73 22.60
Resveratrol (2.5 µM) 60.90 14.00 21.01
Resveratrol (25 µM) 53.90 13.14 21.13
Metformin (5 mM) 69.24 8.82 13.68
Resveratrol (2.5 µM) 70.87 7.26 14.81
+ metformin (5 mM)
Resveratrol (25 µM) 65.48 11.57 15.54
+ metformin (5 mM)
Figure 1. Effects of resveratrol and metformin on DNA damage response in A549 cells, with or without exposure to UVC. In non-UVC exposed conditions, 
cells were treated with resveratrol (2.5 and 25 µM), metformin (5 mM) or in combination (2.5 or 25 µM resveratrol combined with 5 mM metformin) for 48 h. 
For UVC-exposed experiments, cells were primed for 48 h as non-UVC exposed cells, which were then followed by exposure to 20 J/m2 UVC for 10 sec. Both 
UVC exposed and non-exposed cells were maintained in culture for another 4 h and then harvested for further analysis. (A) Changes in p53 protein expression 
in cells treated with different agents with or without UVC exposure were analyzed by western blot analysis. (B) The total protein expression level of γH2AX 
was also determined. The intensity of the specific immunoreactive bands was quantified by densitometry and expressed as a fold difference against actin 
(loading control).
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metformin alone or in combination with resveratrol resulted in 
52-79 and 72-85% suppression of cyclin E and cdk2, respec-
tively. Since resveratrol alone did not significantly change cell 
cycle phase distribution under the conditions of exposure to 
UVC, the observed increase in cyclin E expression along with 
decreasing cdk2 expression following treatment by resveratrol 
may reflect may reflect a compensatory regulatory adjustment 
by cyclin E/cdk2 (Table I). As expected, however, a more 
pronounced decrease in the expression of cyclin E as well as 
cdk2 was detected in the cells treated with 5 mM metformin 
alone or with the addition of 25 µM resveratrol (Fig. 2A). 
Since metformin-treated cells also showed alterations in G2/M 
progression, we assayed the changes in cyclin B/cdk1 expres-
sion. Following metformin treatment, downregulation of 
cyclin B1 (~56%) and cdk1 (~72%) was observed, but no further 
reduction on cdk1 expression occurred in cells treated with 
metformin combined with 2.5 or 25 µM resveratrol (Fig. 2A).
Cyclin E/cdk2 also plays a pivotal role in controlling Rb and 
entry into the S phase. We also examined whether control of 
cyclin E/cdk2 by metformin may result in a change in Rb. We 
found that under the same treatment conditions a ~66% suppres-
sion of Rb was observed that could contribute to the partial 
G1 and S arrest elicited by metformin (Fig. 2B). Additionally, 
we also investigated the effects of metformin and resveratrol 
on the p53-p21 axis of the G1 and S checkpoint control in 
response to the UVC stimuli. Resveratrol (25µM) increased 
p21 expression (1.8-fold); whereas metformin alone or in 
combination with resveratrol resulted in >50% downregulation 
of p21 (metformin alone or with 2.5 µM resveratrol) and ~85% 
decrease of p21 (metformin with 25 µM resveratrol) (Fig. 2B). 
Activation of cyclin B1 and the cyclin B1/cdk1 complex is 
tightly controlled by phosphorylation and de-phosphoryla-
tion via plk1 and cdc25c, respectively (52,53). Therefore, 
cyclin B/cdk1-mediated G2/M progression by metformin and 
resveratrol was further analyzed by the changes in plk1/cdc25c. 
A more pronounced decrease in the expression of plk1/cdc25c 
was detected in the cells treated with 5 mM metformin when 
combined with 25 µM resveratrol (Fig. 2B); in agreement with 
the cyclin B1/cdk1 changes we observed (Fig. 2A).
Control of DNA damage checkpoint and repair by resveratrol 
and metformin under UVC-induced conditions. DNA repair 
plays an important role in DNA damage responses during 
anti-carcinogenesis and anti-aging. Two tumor suppressor 
proteins, checkpoint kinase 2 (Chk2) and p53R2, associated 
Figure 2. Changes in expression of various cell cycle regulatory proteins under UVC-exposed conditions following different treatments. A549 cells were 
primed with resveratrol (2.5 and 25 µM), metformin (5 mM) or in combination (2.5 or 25 µM resveratrol combined with 5 mM metformin) for 48 h and exposed 
to 20 J/m2 UVC for 10 sec. Then cells were maintained in culture for another 4 h and harvested for further analysis. (A) Western blot analysis of the changes in 
cyclin E, cdk2, cyclin B1 and cdk1 protein expression. (B) The total protein expression levels of Rb, p21, plk1 and cdc25c were also determined by western blot 
analysis. The intensity of the specific immunoreactive bands was quantified by densitometry and expressed as a fold difference against actin (loading control).
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with DNA damage checkpoint and DNA repair were further 
analyzed in response to UVC. In cells treated with resveratrol, 
p-chk2 and p53R2 were upregulated (Fig. 3), suggesting the 
activation of DNA repair by resveratrol under UVC treatment as 
a cellular protective mechanism from DNA damage. Metformin 
alone or in combination with resveratrol also resulted in the 
upregulation of p53R2 (Fig. 3) while downregulation of p-chk2 
was found in cells treated with metformin alone or combined 
with resveratrol (Fig. 3). These results suggest that in cells 
exposed to UVC, metformin alone or with addition of resvera-
trol likely induces DNA repair via the upregulation of p53R2 
without concomitantly invoking the activation of chk2.
Discussion
In previous studies, we examined multiple gero-preventive 
agents by focusing on their activity in controlling the mTOR/S6 
signaling pathway (54). Both metformin and resveratrol were 
found to reduce constitutive DNA damage as indicated by 
the inhibition of the phosphorylation of H2AX (γH2AX) and 
ribosomal S6 protein expression (54). These results suggest 
that metformin and resveratrol, previously regarded as prime 
candidates for treating and preventing type II diabetes (12,13) 
and coronary heart disease (25-28), may offer the potential to 
be repositioned as candidate anti-aging drugs via the modula-
tion of intrinsic aging factors. Indeed, the interest in resveratrol 
and metformin as gero-active chemicals may have started 
much earlier stemming from efforts to identify and develop 
caloric restriction mimetics (CRMs) based on the longstanding 
observation of McCay in the 1930s that a reduction in caloric 
intake retarded aging and extended median and maximal life 
span (55,56). Metformin, a biguanide currently considered the 
primary stay of management for diabetes, acts as a CRM in 
whole organisms by a multitude of mechanisms including at 
the metabolic level, the facilitation of fatty acid oxidation and 
glucose uptake in peripheral tissues as well as the suppression 
of hepatic gluconeogenesis. Molecularly, metformin not only 
serves as a sensor/modulator of cellular energy status, but also 
as an activator and inhibitor of AMPK and mTOR, respec-
tively, in line with the vital role it plays in growth control. 
In tumorigenic settings, ample evidence has been obtained 
that exposure to metformin shows efficacy in patients diag-
nosed with malignant diseases including pancreatic (57) and 
breast cancer (58), and colorectal polyps (59). Since cancer 
is a disease associated with aging, it is not totally surprising 
that metformin also harnesses the capacity to improve life 
expectancy as befitting of a gero-protective agent. The same 
considerations may apply to resveratrol (14-19); its efficacy has 
been verified in all three stages of carcinogenesis (initiation, 
promotion and progression) in UVB and chemically induced 
skin tumor growth in mice (23,42) and in numerous animal 
models of human types of cancers (18,19). To date, the roles 
of resveratrol and metformin in preventing environmentally 
induced external damage that contribute to aging remain 
largely unknown.
In the present study, we focused on the roles resveratrol 
and metformin play in modulating the cellular and molecular 
changes in cancer cells elicited in response to UV challenge 
using as a model UVC-stressed and unstressed A549 cells. 
Specifically, DNA damage responses by resveratrol and 
metformin were assessed using changes in the level of expres-
sion of p53 and γH2AX. Our results showed that metformin 
at 5 mM significantly prevented the UVC-induced upregula-
tion of p53; relatively, much less inhibition on UVC-induced 
p53 expression was observed in cells treated with resve-
ratrol (Fig. 1A). In addition, inhibition of UVC-induced 
γH2AX expression was only observed in metformin and not 
resveratrol treatment conditions (Fig. 1B). These findings 
suggest that metformin has better preventive potential against 
UVC-induced DNA damage compared to resveratrol.
Flow cytometric analysis showed differential effects on cell 
cycle control by metformin and resveratrol in UVC-exposed 
cells (Table I). Metformin resulted in G1 arrest and prevention 
of S and G2/M entry accompanied by the inhibition in cell 
cycle-associated regulatory proteins, vis-à-vis, cyclin E/cdk2, 
Rb, p21 cyclin B1/cdk1 and plk1 (Fig. 2A and B). As well, 
metformin downregulated p-chk2, known to be involved in a 
p53-dependent cell cycle checkpoint for DNA damage (Fig. 3). 
In contrast, no significant change in cell cycle transition 
occurred in UVC-induced cells following resveratrol treat-
ment (Table I), and only moderate changes to the above 
mentioned G1 and S and G2/M cell cycle regulatory proteins 
as well as p-chk2 were observed (Figs. 2A and B, and 3). It 
is also notable that the metformin induced cell cycle arrest 
at the G1 and S checkpoint under UVC conditions was not 
mediated via the p53-p21 axis, but did show a correlation 
with the reduction in cyclin E/cdk2 and Rb (Fig. 2). Since 
metformin-mediated cell cycle control is decoupled from 
p53/p21, we also tested control of p53-mediated DNA repair 
by the changes in p53R2, a recently discovered DNA repair 
regulatory protein (60-62). Upregulation of p53R2 expression 
by metformin after UVC exposure was also observed (Fig. 3). 
The effects of metformin on UVC-induced cells may therefore 
be summarized as to include: i) the prevention of UVC-induced 
DNA damage as supported by downregulation of p-chk2, 
p53 and γH2AX (Figs. 1 and 3); ii) induction of cell cycle 
arrest (Table Ι) decoupled from p53/p21; and iii) fortification of 
DNA repair through p53-independent control of p53R2 (Fig. 3).
Compared to metformin, resveratrol as a single agent is 
marginally effective in UVC-exposed cells, suggesting that it 
operates by a different mechanism. This possibility is supported 
by our results showing that, as related to the prevention of 
Figure 3. Control of DNA damage checkpoint and repair by resveratrol and 
metformin under UVC-exposed conditions in A549 cells. Conditions of 
priming, treatment and analysis were identical to those described in Fig. 2 
legend. The total protein expression levels of p-chk2 and p53R2 were deter-
mined. The intensity of the specific immunoreactive bands was quantified 
by densitometry and expressed as a fold difference against actin (loading 
control). 
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DNA damage in UVC-exposed A549 cells, synergism occurs 
between these two agents since cells are more susceptible 
to the co-treatment regimen than to each individual agent. 
This conclusion is made evident by the following results: 
i) suppression of DNA damage based on the downregulation 
of γH2AX/p53/p-chk2 (Figs. 1 and 3); ii) inhibition of cell 
cycle progression via modulation of cyclin E/cdk2, Rb, 
p21 cyclin B1/cdk1 and plk1/cdc25c (Fig. 2A and B); and 
iii) enhancement of DNA repair indicated by the upregulation 
of p53R2 (Fig. 3).
In conclusion, our results revealed the mechanistic aspects 
that underlie or contribute to the beneficial effects of metformin 
and resveratrol, two readily available and widely used agents, 
regarding their potential as single or combined candidates for 
conferring protection against UV-induced DNA damage and 
hence reducing the risk of aging.
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